tetano
Editor, Senior Moderator
Clin Lab Med
. 2022 Mar;42(1):31-56.
doi: 10.1016/j.cll.2021.10.005. Epub 2021 Nov 3.
Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology
Lucy Ochola[SUP] 1 [/SUP], Paul Ogongo[SUP] 2 [/SUP], Samuel Mungai[SUP] 3 [/SUP], Jesse Gitaka[SUP] 3 [/SUP], Sara Suliman[SUP] 4 [/SUP]
Affiliations
Abstract
The coronavirus disease of 2019 (COVID-19) pandemic, caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has undoubtedly resulted in significant morbidities, mortalities, and economic disruptions across the globe. Affordable and scalable tools to monitor the transmission dynamics of the SARS-CoV-2 virus and the longevity of induced antibodies will be paramount to monitor and control the pandemic as multiple waves continue to rage in many countries. Serologic assays detect humoral responses to the virus, to determine seroprevalence in target populations, or induction of antibodies at the individual level following either natural infection or vaccination. With multiple vaccines rolling out globally, serologic assays to detect anti-SARS-CoV-2 antibodies will be important tools to monitor the development of herd immunity. To address this need, serologic lateral flow assays (LFAs), which can be easily implemented for both population surveillance and home use, will be vital to monitor the evolution of the pandemic and inform containment measures. Such assays are particularly important for monitoring the transmission dynamics and durability of immunity generated by natural infections and vaccination, particularly in resource-limited settings. In this review, we discuss considerations for evaluating the accuracy of these LFAs, their suitability for different use cases, and implementation opportunities.
Keywords: COVID-19; Diagnostics; LFAs; SARS-CoV-2; Serology.
. 2022 Mar;42(1):31-56.
doi: 10.1016/j.cll.2021.10.005. Epub 2021 Nov 3.
Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology
Lucy Ochola[SUP] 1 [/SUP], Paul Ogongo[SUP] 2 [/SUP], Samuel Mungai[SUP] 3 [/SUP], Jesse Gitaka[SUP] 3 [/SUP], Sara Suliman[SUP] 4 [/SUP]
Affiliations
- PMID: 35153047
- DOI: 10.1016/j.cll.2021.10.005
Abstract
The coronavirus disease of 2019 (COVID-19) pandemic, caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has undoubtedly resulted in significant morbidities, mortalities, and economic disruptions across the globe. Affordable and scalable tools to monitor the transmission dynamics of the SARS-CoV-2 virus and the longevity of induced antibodies will be paramount to monitor and control the pandemic as multiple waves continue to rage in many countries. Serologic assays detect humoral responses to the virus, to determine seroprevalence in target populations, or induction of antibodies at the individual level following either natural infection or vaccination. With multiple vaccines rolling out globally, serologic assays to detect anti-SARS-CoV-2 antibodies will be important tools to monitor the development of herd immunity. To address this need, serologic lateral flow assays (LFAs), which can be easily implemented for both population surveillance and home use, will be vital to monitor the evolution of the pandemic and inform containment measures. Such assays are particularly important for monitoring the transmission dynamics and durability of immunity generated by natural infections and vaccination, particularly in resource-limited settings. In this review, we discuss considerations for evaluating the accuracy of these LFAs, their suitability for different use cases, and implementation opportunities.
Keywords: COVID-19; Diagnostics; LFAs; SARS-CoV-2; Serology.